全文获取类型
收费全文 | 3102篇 |
免费 | 153篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 28篇 |
儿科学 | 56篇 |
妇产科学 | 47篇 |
基础医学 | 537篇 |
口腔科学 | 91篇 |
临床医学 | 265篇 |
内科学 | 568篇 |
皮肤病学 | 17篇 |
神经病学 | 327篇 |
特种医学 | 145篇 |
外科学 | 532篇 |
综合类 | 30篇 |
预防医学 | 113篇 |
眼科学 | 32篇 |
药学 | 181篇 |
中国医学 | 7篇 |
肿瘤学 | 290篇 |
出版年
2023年 | 8篇 |
2022年 | 28篇 |
2021年 | 65篇 |
2020年 | 31篇 |
2019年 | 45篇 |
2018年 | 49篇 |
2017年 | 34篇 |
2016年 | 72篇 |
2015年 | 93篇 |
2014年 | 92篇 |
2013年 | 119篇 |
2012年 | 190篇 |
2011年 | 219篇 |
2010年 | 104篇 |
2009年 | 133篇 |
2008年 | 186篇 |
2007年 | 235篇 |
2006年 | 214篇 |
2005年 | 219篇 |
2004年 | 208篇 |
2003年 | 208篇 |
2002年 | 203篇 |
2001年 | 55篇 |
2000年 | 24篇 |
1999年 | 27篇 |
1998年 | 43篇 |
1997年 | 40篇 |
1996年 | 28篇 |
1995年 | 28篇 |
1994年 | 25篇 |
1993年 | 15篇 |
1992年 | 13篇 |
1991年 | 21篇 |
1990年 | 27篇 |
1989年 | 11篇 |
1988年 | 12篇 |
1986年 | 6篇 |
1985年 | 6篇 |
1984年 | 10篇 |
1983年 | 5篇 |
1982年 | 12篇 |
1981年 | 11篇 |
1978年 | 7篇 |
1977年 | 8篇 |
1976年 | 5篇 |
1975年 | 11篇 |
1974年 | 5篇 |
1973年 | 7篇 |
1972年 | 5篇 |
1971年 | 12篇 |
排序方式: 共有3266条查询结果,搜索用时 17 毫秒
51.
Dietmar Springer Liane D Paul Roland F Staack Thomas Kraemer Hans H Maurer 《Drug metabolism and disposition》2003,31(8):979-982
4'-Methyl-alpha-pyrrolidinopropiophenone (MPPP) is a new drug of abuse. It is believed to have an abuse potential similar to that of amphetamines. Previous studies with Wistar rats had shown that MPPP was metabolized mainly by hydroxylation in position 4' followed by dehydrogenation to the corresponding carboxylic acid. The aim of the study presented here was to identify the human hepatic cytochrome p450 (p450) enzymes involved in the biotransformation of MPPP to 4'-hydroxymethyl-pyrrolidinopropiophenone. Baculovirus-infected insect cell microsomes and human liver microsomes were used for this purpose. Only CYP2C19 and CYP2D6 catalyzed this hydroxylation. The apparent Km and Vmax values for the latter were 9.8 +/- 2.5 microM and 13.6 +/- 0.7 pmol/min/pmol p450, respectively. CYP2C19 was not saturable over the tested substrate range (2-1000 microM) and interestingly showed a biphasic kinetic profile with apparent Km,1 and Vmax,1 values of 47.2 +/- 12.5 microM and 8.1 +/- 1.4 pmol/min/pmol p450, respectively. Experiments with pooled human liver microsomes also revealed biphasic nonsaturable kinetics with apparent Km,1 and Vmax,1 values of 57.0 +/- 20.9 microM and 199.7 +/- 59.7 pmol/min/mg of protein for the high affinity enzyme, respectively. Incubation of 2 microM MPPP with 3 microM of the CYP2D6-specific inhibitor quinidine resulted in significant (p < 0.01) turnover inhibition (11.8 +/- 1.6% of control). Based on kinetic data corrected for the relative activity factors, CYP2D6 is the enzyme mainly responsible for MPPP hydroxylation, confirmed by CYP2D6 inhibition studies. 相似文献
52.
Growth Regulation of Thyroid and Thyroid Tumors in Humans 总被引:1,自引:0,他引:1
In a study of growth regulation of the human thyroid gland and thyroid tumors we investigated the impact of iodine and that
of the thyroid-specific growth-stimulating hormone TSH. Further studies included locally active growth factors such as the
epidermal growth factor, insulin-like growth factor, and tissue transforming growth factors alpha and beta. In addition to
studies of growth regulation by the various growth factors in mostly normal thyrocytes, the impact of tumor-specific mutations
in oncogenes and tumor-suppressor genes was investigated. The results demonstrated distinct changes in tissue specificity
and sensitivity to external stimuli. This rather complex view on thyrocyte growth regulation may be confusing, but it describes
the biologic reality more precisely. Increased knowledge of the regulatory processes may lead to the development of new tumor-
and patient-specific therapeutic approaches, especially for preventing benign goiter recurrence and for treating follicular
and papillary thyroid cancers. 相似文献
53.
54.
BACKGROUND AND PURPOSE: In 1990 the skin source measuring bridge was proposed as a tool to measure (1) the distance between the interstitial implant and the overlying skin during brachytherapy boost treatment as well as (2) the distances between the lateral source end and the exit point of the guide needle. The present study reports on the clinical experience using the source skin measuring bridge with respect to incidence and grade of teleangiectasia, and their relation to source skin distances and doses. PATIENTS AND METHODS: Two hundred and twenty-two breast cancer patients (229 breasts) treated between 1983 and 1996 with breast conserving therapy including a brachytherapy boost were scored on the occurrence of teleangiectasia. The minimum distance between the sources (above implant and laterally) and the skin surface were measured. RESULTS: If no bridge was used the appearance of teleangiectasia in the epiderm above the implant is 77, 63 and 50% for boost doses of 25, 20 and 15 Gy, respectively. For brachytherapy boost doses of 25 and 20 Gy and distances smaller than 10mm between the implant and the overlying epiderm, as determined with the skin source measuring bridge, the appearance of teleangiectasia was 78 and 46%, respectively. When respecting provisional dosimetry to spare the skin for a boost dose of 15 Gy, resulting in distances between 10 and 15 mm for the implant overlying skin and distances between 5 and 10 mm for the lateral skin, teleangiectasia can be reduced to a minimum (6.3% above and 3.3% laterally). While in a univariate analysis several parameters (use of the bridge, boost dose, boost modality, external beam therapy modality) were predictive factors, the use of the bridge remained the only significant variable in a multivariate analysis. CONCLUSIONS: The skin source measuring bridge reduces teleangiectasia after interstitial brachytherapy boost treatment. A hypothesis made previously relating teleangiectasia and source skin distances was verified and extended. Even when 3D planning is used, the bridge allows for a provisional calculation of the security margins between source positions and the skin at the time of BT implantation to assure a correct needle positioning from the beginning, instead of correcting dwell times later on to avoid unnecessary high skin doses. 相似文献
55.
Four therapists' participation in six therapies were analyzed at the utterance level. Therapist's utterances (N= 5,504) were rated on 39 categories of the Stuttgart Interactional Category System in two early, two middle, and two late sessions, providing a primary and a cross-validation sample. Application of the P-technique revealed four stable and reliable therapist participatory factors (i.e., Objective Information Exchange Seeking, Directing Insightful/Painful Work, Self-Involving Disclosure, and Advice Giving Information), accounting for 39% of the total variance. Multivariate analyses revealed a significant therapist by phase interaction on all factors, with most differences occurring on the work and disclosure factors in the middle phase and between two groups of therapists (within treatments). Further examination using chronographic analyses revealed (1) some shortcomings in the analysis of variance approach, and (2) significant strengths in identifying naturally occurring episodes of therapist participation. Results are discussed in terms of the need to further develop the use of the P-technique to discover generalizable structures of therapist participation and to track quantitative variations in such structures using chronographic analysis. 相似文献
56.
Comparative evaluation of a heparin‐citrate anticoagulation for LDL‐apheresis in two primary apheresis systems
下载免费PDF全文
![点击此处可从《Journal of clinical apheresis》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Doris Handschel Michiel Etienne Janssens Marion Gericke Stef De Reys Helmut Borberg 《Journal of clinical apheresis》2017,32(5):319-328
BACKGROUND: As COBE Spectra has been replaced in many parts of the world, we describe a new protocol for low‐density lipoprotein (LDL)‐apheresis performed on familial hypercholesterolemia patients for the Spectra Optia platform. METHODS: For all procedures, after administering a bolus of heparin of 2,500 U, 10,000 U of heparin added to a 600 ml ACD‐A bag was used as anticoagulant (AC). In a first phase (A), 16 apheresis procedures with COBE Spectra using an inlet:AC ratio of 25:1 were compared to 18 LDL‐apheresis treatments with Spectra Optia at split Inlet:AC ratios of 16:1/18:1 or 20:1/25:1. Platelet activation and coagulation markers were assessed. In a follow‐up phase (B), 20 procedures on Spectra Optia using an inlet:AC ratio of 20:1 were performed. RESULTS: Although coagulation markers and platelet activation analyzed were similar in both apheresis devices used, COBE Spectra procedures did not show any visual clumping in the sets. Visual analysis of clumping was highest in the Spectra Optia's 20:1/25:1 AC regimen (5/8 procedures). For the lowest Spectra Optia, AC regimen and during the follow‐up phase reversible clump formation in the disposable set was similar (1/10 procedures). Clumping was successfully reversed in all cases by temporarily lowering the inlet:AC ratio to 18:1. Blood cell counts (WBC, Plt, Hct) were similar for both COBE Spectra and Spectra Optia procedures. Spectra Optia had a significantly higher plasma removal efficiency versus COBE Spectra (84% vs.75%, P < .05). No serious adverse events were observed. CONCLUSION: Apheresis procedures on the Spectra Optia system with low‐dose heparin‐citrate anticoagulation are feasible and safe. 相似文献
57.
58.
Vision is the most important sense for humans and it is irreversibly impaired by axonal damage of retinal ganglion cells (RGCs) in the optic nerve due to the lack of axonal regeneration. The failure of regeneration is partially attributable to factors located in the inhibitory environment of the forming glial scar and myelin as well as an insufficient intrinsic ability for axonal regrowth. Moreover, RGCs undergo apoptotic cell death after optic nerve injury, eliminating any chance for regeneration. In this review, we discuss the different aspects that cause regenerative failure in the optic nerve. Moreover, we describe discoveries of the last two decades demonstrating that under certain circumstances mature RGCs can be transformed into an active regenerative state allowing these neurons to survive axotomy and to regenerate axons in the injured optic nerve. In this context we focus on the role of the cytokines ciliary neutrophic factor (CNTF) and leukemia inhibitory factor (LIF), their receptors and the downstream signaling pathways. Furthermore, we discuss strategies to overcome inhibitory signaling induced by molecules associated with optic nerve myelin and the glial scar as well as the regenerative outcome after combinatorial treatments. These findings are encouraging and may open the possibility that clinically meaningful regeneration may become achievable one day in the future. 相似文献
59.
60.